Newsletter: May 2023

Financial Results

WuXi Biologics Reports Remarkable 2022 Annual Results

WuXi Biologics is pleased to announce its audited annual results for the year ended December 31, 2022. 2022 was a year of continued strong performance and implementation of the “Follow and Win the Molecule” strategies. With the ongoing efforts of the teams and by leveraging its unique CRDMO business model, the Group continued to navigate the challenging macro environment, delivered outstanding growth on both the topline and bottom line, and fulfilled its commitment to its customers as the enabling partner by accelerating and transforming the discovery, development and manufacturing of novel biologics, benefiting patients worldwide.

Partner News

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

Under the terms of the agreement, GSK will be granted an exclusive global license for the research, development, manufacturing, and commercialization of a pre-clinical bispecific antibody that crosslinks tumor cells and T cells by targeting a tumor-associated antigen (TAA) on tumor cells and CD3 expression on T cells and up to three additional preclinical TCE antibodies currently at an earlier discovery stage.

WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

WuXi XDC and Cidara Therapeutics Expand Collaboration to Advance Cidara’s Oncology DFC Program

WuXi XDC Congratulates EDDC on FDA Clearance of IND Application for First Made-in-Singapore Antibody-Drug Conjugate

New Publications and Articles

Responding to a Changing Drug Product Global Supply Chain

Current Trends in Host Cell Protein Detection for Biologics Manufacturing

Dr. Weichang Zhou, CTO of WuXi Biologics: Secure the Future of Bioprocessing

Featured Video

WuXi XDC – Your Single Source ADC Development Solution

Awards

WuXi Biologics Ireland Limited Wins 2023 FOYA Award for Operations

WuXi Biologics Receives CDMO Leadership Awards for Sixth Consecutive Year Sustainability Commitment

WuXi Biologics Receives Best CDMO and Bioprocessing Excellence Awards

Environmental, Social, and Governance

WuXi Biologics Release 2022 ESG Report Detailing its Continued Commitment to Sustainability

WuXi Biologics Receives The Asset ESG Corporate Platinum Award for Second Consecutive Year

WuXi Biologics Recognized as Both Industry and Regional Top-Rated Company by Sustainalytics.